Posts

Showing posts with the label tumor mutation burden

PD-L1 vs TMB vs MSI-H: Which Biomarker Best Predicts Immunotherapy Response?

Image
PD-L1, Tumor Mutation Burden (TMB), and Microsatellite Instability-High (MSI-H) are among the most important biomarkers used to predict whether a cancer patient is likely to benefit from immunotherapy. While MSI-H is generally considered the strongest single predictor of response, no biomarker is perfect. Many oncologists now combine PD-L1, TMB, MSI-H, genomic profiling, and clinical factors to make treatment decisions. In general: MSI-H often provides the strongest prediction of immunotherapy response. High TMB may increase the likelihood of benefit from checkpoint inhibitors. High PD-L1 expression can help identify patients more likely to respond, especially in lung cancer. The best predictions often come from combining multiple biomarkers rather than relying on just one. Why Biomarkers Matter in Immunotherapy Immunotherapy has transformed cancer treatment. Some patients with advanced cancer achieve long-lasting remissions that were once considered impossible. However, not all patien...

Tumor Mutation Burden (TMB): The Immunotherapy Biomarker That Helps Predict Treatment Success (2026)

Image
Quick Answer Tumor Mutation Burden (TMB) measures the number of genetic mutations within a cancer's DNA. Tumors with a high TMB often produce more abnormal proteins (neoantigens), making them easier for the immune system to recognize and attack. As a result, patients with high-TMB tumors may be more likely to benefit from immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab. However, TMB is not a perfect biomarker. Some patients with high TMB fail to respond to immunotherapy, while others with low TMB experience remarkable and durable responses. Key Takeaways TMB measures the number of mutations within a tumor. High-TMB tumors tend to generate more neoantigens. More neoantigens may increase immune recognition. High TMB is associated with improved responses to some immunotherapies. The FDA has approved immunotherapy for certain high-TMB cancers. TMB should be interpreted alongside PD-L1, MSI-H status, and other biomarkers. TMB is an important component of pr...

Archive

Show more